Retatrutide is a novel therapeutic/treatment/medicine agent under investigation for the management/treatment/control of type 2 diabetes. It belongs to a class of drugs known as GLP-1 receptor agonists/glucagon-like peptide-1 receptor agonists/glucose-dependent insulinotropic polypeptide agonists, which work by stimulating/activating/enhancing the r… Read More

Emerging in the field of obesity therapy, retatrutide presents a unique approach. Beyond many existing medications, retatrutide functions as a twin agonist, simultaneously targeting both GLP-like peptide-1 (GLP-1) and glucose-responsive insulinotropic polypeptide (GIP) binding sites. The concurrent engagement promotes several beneficial effects, li… Read More